BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 18156608)

  • 1. Minor emtricitabine intolerance in treatment-stable patients switched from tenofovir/lamivudine to a fixed-dose combination of tenofovir/emtricitabine (Truvada).
    Palacios R; Terrón A; Hidalgo A; Rivero A; Santos J;
    J Antimicrob Chemother; 2008 Feb; 61(2):462-3. PubMed ID: 18156608
    [No Abstract]   [Full Text] [Related]  

  • 2. Meeting notes from ICAAC. Tenofovir + emtricitabine vs. AZT + 3TC.
    Feinberg J
    AIDS Clin Care; 2005 Jan; 17(1):7. PubMed ID: 15717373
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study.
    Stellbrink HJ; Orkin C; Arribas JR; Compston J; Gerstoft J; Van Wijngaerden E; Lazzarin A; Rizzardini G; Sprenger HG; Lambert J; Sture G; Leather D; Hughes S; Zucchi P; Pearce H;
    Clin Infect Dis; 2010 Oct; 51(8):963-72. PubMed ID: 20828304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-HIV agents. Dueling nukes: AZT + 3TC vs. tenofovir + FTC.
    TreatmentUpdate; 2005; 17(5):5-7. PubMed ID: 17225279
    [No Abstract]   [Full Text] [Related]  

  • 5. Combination antiretroviral therapy with tenofovir, emtricitabine or lamivudine, and nevirapine.
    Redfield RR; Morrow JS
    Clin Infect Dis; 2008 Oct; 47(7):984-5. PubMed ID: 18778234
    [No Abstract]   [Full Text] [Related]  

  • 6. [First line therapy. Tenofovir DF/emtricitabine--the potent backbone].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():12-4. PubMed ID: 19024908
    [No Abstract]   [Full Text] [Related]  

  • 7. Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers.
    Blum MR; Chittick GE; Begley JA; Zong J
    J Clin Pharmacol; 2007 Jun; 47(6):751-9. PubMed ID: 17519400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The art of managing human immunodeficiency virus infection: a balancing act.
    Reiss P
    Clin Infect Dis; 2009 Nov; 49(10):1602-4. PubMed ID: 19842978
    [No Abstract]   [Full Text] [Related]  

  • 9. [Two novel fixed formulations of nucleoside analogues (tenofovir-emtricitabine, and abacavir-lamivudine). Prospective, open study on clinical practice and therapeutic perspectives, in patients naïve and in subjects pre-treated with antiretrovirals].
    Manfredi R; Calza L
    Recenti Prog Med; 2008 Oct; 99(10):492-501. PubMed ID: 19040127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone.
    Muñoz de Benito RM; Arribas López JR
    Expert Rev Anti Infect Ther; 2006 Aug; 4(4):523-35. PubMed ID: 17009933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tenofovir regimen compared with Combivir.
    AIDS Patient Care STDS; 2005 Jan; 19(1):59-60. PubMed ID: 15700398
    [No Abstract]   [Full Text] [Related]  

  • 12. Tenofovir/emtricitabine combination results in lower bone-mineral density.
    AIDS Patient Care STDS; 2010 Apr; 24(4):265-6. PubMed ID: 20405529
    [No Abstract]   [Full Text] [Related]  

  • 13. Two-once-daily fixed-dose NRTI combinations for HIV.
    Med Lett Drugs Ther; 2005 Feb; 47(1203):19-20. PubMed ID: 15767973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of tenofovir-emtricitabine versus abacavir-lamivudine.
    Landman GW; Soonawala D
    Clin Infect Dis; 2010 Apr; 50(8):1200; author reply 1200. PubMed ID: 20233045
    [No Abstract]   [Full Text] [Related]  

  • 15. Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients.
    Lapadula G; Costarelli S; Quiros-Roldan E; Calabresi A; Izzo I; Carosi G; Torti C
    Clin Infect Dis; 2008 Apr; 46(7):1127-9. PubMed ID: 18444839
    [No Abstract]   [Full Text] [Related]  

  • 16. Rapid improvement in fasting lipids and hepatic toxicity after switching from didanosine/lamivudine to tenofovir/emtricitabine in patients with toxicity attributable to didanosine.
    Palacios R; Rivero A; Santos I; Ríos MJ; Castaño M; del Arco A; Santos González J;
    HIV Clin Trials; 2010; 11(2):118-20. PubMed ID: 20542848
    [No Abstract]   [Full Text] [Related]  

  • 17. Tapping into combination pills for HIV.
    Hughes B
    Nat Rev Drug Discov; 2009 Jun; 8(6):439-40. PubMed ID: 19483700
    [No Abstract]   [Full Text] [Related]  

  • 18. Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine.
    Gutiérrez S; Guillemi S; Jahnke N; Montessori V; Harrigan PR; Montaner JS
    Clin Infect Dis; 2008 Feb; 46(3):e28-30. PubMed ID: 18181733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.
    Chetchotisakd P
    Expert Rev Anti Infect Ther; 2009 Sep; 7(7):801-5. PubMed ID: 19735222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Simply convincing. New fixed combination for HIV therapy].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():20-3. PubMed ID: 16385865
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.